Every Form 4 that Quoin Pharmaceuticals, Ltd. American (QNRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow QNRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QNRX filings page.
Quoin Pharmaceuticals, Ltd. (QNRX) director and Chief Operating Officer Denise P. Carter reported net purchases on August 31, 2026. She purchased 20,490 ADSs at $4.88 per ADS in a private placement and acquired 10,245 ordinary warrants with a $6.10 exercise price, giving the right to buy 10,245 ADSs. Each ADS represents 35 ordinary shares. The warrants are immediately exercisable, subject to a beneficial ownership cap, and will expire on the earlier of five years from issuance or 30 days after Quoin publicly announces that the primary endpoint has been met in clinical trial CL-QRX003-004 for Netherton Syndrome. Following the ADS purchase, Carter directly owns 37,709 ADSs.
Quoin Pharmaceuticals, Ltd. (QNRX) reports that Chief Executive Officer Michael Myers purchased both ADSs and warrants in a private placement. On 2026-08-31, he acquired 20,490 ADSs at a combined purchase price of $4.88 per ADS plus accompanying ordinary warrants, increasing his direct ADS holdings to 37,713. In the same transaction, he acquired 10,245 Ordinary Warrants, each exercisable for one ADS at an exercise price of $6.10 per ADS, subject to a beneficial ownership cap. The warrants are exercisable immediately and will expire on the earlier of five years from issuance or 30 days after a public announcement that the primary endpoint has been met in clinical trial CL-QRX003-004 for Netherton Syndrome.
Quoin Pharmaceuticals, Ltd. (QNRX) reported that Chief Financial Officer Sally Bridget Lawlor purchased 10,244 ADSs on August 31, 2026 at $4.88 per ADS in a private placement that included 50% warrant coverage. She also acquired 5,122 ordinary warrants exercisable at $6.10 per ADS, which became exercisable immediately subject to a beneficial ownership cap and will expire on the earlier of five years from issuance or 30 days after Quoin publicly announces that the primary endpoint has been met in clinical trial CL-QRX003-004 for Netherton Syndrome. Following these purchases, she directly owned 10,684 ADSs and 5,122 warrants.
Quoin Pharmaceuticals, Ltd. (QNRX) director Anthony James Culverwell reported buying both ADSs and warrants linked to the company. On 2026-08-31 he purchased 6,146 ADSs at $4.88 per ADS in a private placement that included 50% ordinary warrant coverage, and also acquired 3,073 ordinary warrants with an exercise price of $6.10 per ADS. Each ADS represents 35 ordinary shares. The warrants are exercisable immediately, subject to a beneficial ownership cap, and will expire on the earlier of five years from issuance or 30 days after Quoin publicly announces that the primary endpoint has been met in clinical trial CL-QRX003-004 for Netherton Syndrome. Following the ADS purchase, Culverwell directly held 40,364 ADSs.
Quoin Pharmaceuticals, Ltd. (QNRX) reported that director Dennis Langer acquired 34,534 ADSs on August 27, 2026 in a grant/award-type transaction. The company and Langer entered an exchange agreement under which $177,849 of accrued interest on a previously purchased note was exchanged for these ADSs at $5.15 per ADS. Following this debt-for-equity exchange, Langer directly holds 56,243 ADSs. Each ADS represents 35 ordinary shares of Quoin Pharmaceuticals.
Quoin Pharmaceuticals, Ltd. (QNRX) reported that director Anthony James Culverwell acquired 31,352 ADSs on August 27, 2026 through a grant/award acquisition. The ADSs were issued under an exchange agreement in which $161,461 of accrued interest outstanding on a note he previously purchased was exchanged for these shares, at a reported value of $5.15 per ADS. Following this transaction, he holds 34,218 ADSs directly. Each ADS represents 35 ordinary shares. The exchange agreement and the debt-for-equity exchange were approved in advance by Quoin’s audit committee and board of directors.
Quoin Pharmaceuticals, Ltd. reported a Form 4 filing by Stonepine Capital Management, LLC, identified as a ten percent owner of QNRX. The summarized data shows no reported purchases, sales, exercises, gifts, or other share transactions in this filing.
Quoin Pharmaceuticals (QNRX) reported a new stock option grant to its Chief Financial Officer, Sally Bridget Lawlor. On February 4, 2026, she received an option to purchase 85,250 American Depositary Shares (ADS) at an exercise price of $7.37 per ADS.
The option covers ADSs, each representing thirty-five ordinary shares of Quoin Pharmaceuticals. The award vests over four years, with 20% vesting on each of February 4, 2027, 2028 and 2029, and the remaining 40% vesting on February 4, 2030. The option expires on February 4, 2036 and is held directly by the CFO.
Quoin Pharmaceuticals director Joseph Patrick Cooper reported receiving a new stock option grant. On February 4, 2026, he was awarded options to acquire 8,141 American Depositary Shares at an exercise price of $7.37 per ADS. Each ADS represents thirty-five ordinary shares of Quoin Pharmaceuticals.
The options vest over four years, with 20% becoming exercisable on each of February 4, 2027, 2028, and 2029, and the remaining 40% vesting on February 4, 2030. After this grant, Cooper beneficially owns 8,141 derivative securities directly.
Quoin Pharmaceuticals director granted stock options
Quoin Pharmaceuticals, Ltd. reported that director Anthony James Culverwell received a grant of share options on February 4, 2026. The award covers 21,709 American Depositary Shares (ADSs), each with an exercise price of $7.37 per ADS and no purchase price for the grant itself.
Each ADS represents thirty-five ordinary shares of the company. The option vests over four years, with 20% vesting on each of February 4, 2027, February 4, 2028 and February 4, 2029, and the remaining 40% vesting on February 4, 2030. After this transaction, Culverwell directly holds options over 21,709 ADSs.
Quoin Pharmaceuticals (QNRX) reported an equity award to its CEO and director, Michael Myers. On February 4, 2026, he received a share option covering 318,750 American Depositary Shares (ADSs) at an exercise price of $7.37 per ADS, with no purchase price paid for the grant itself.
The option becomes exercisable in four annual installments: 20% of the ADSs vest on each of February 4, 2027, 2028 and 2029, and 40% vest on February 4, 2030. The option expires on February 4, 2036 and is held directly.
Quoin Pharmaceuticals reported an equity award to its Chief Operating Officer and director Denise P. Carter. On February 4, 2026, she received a share option covering 318,750 American Depositary Shares (ADSs) with an exercise price of $7.37 per ADS, expiring on February 4, 2036.
Each ADS represents thirty-five ordinary shares of Quoin Pharmaceuticals. The option vests in four annual installments, with 20% vesting on each of February 4, 2027, 2028 and 2029, and the remaining 40% vesting on February 4, 2030. Following this grant, she beneficially owns 318,750 derivative securities directly.
Quoin Pharmaceuticals director Dennis Langer received a grant of stock options linked to American Depositary Shares (ADSs). On February 4, 2026, he was awarded options to acquire 21,709 ADSs at an exercise price of $7.37 per ADS. Each ADS represents thirty-five ordinary shares of Quoin Pharmaceuticals. The options vest over four years, with 20% vesting on each of February 4, 2027, 2028, and 2029, and the remaining 40% vesting on February 4, 2030. Following this grant, Langer beneficially owns 21,709 derivative securities directly.
Quoin Pharmaceuticals director Michael T. Sember received a new stock option grant. On February 4, 2026, he was awarded a Share Option (Right to Buy) covering 8,141 American Depositary Shares (ADSs) of Quoin Pharmaceuticals, Ltd. at an exercise price of $7.37 per ADS.
Each ADS represents thirty-five ordinary shares of the company. The option vests over four annual installments, with 20% vesting on each of February 4, 2027, 2028 and 2029, and the remaining 40% vesting on February 4, 2030. Following this grant, Sember holds 8,141 derivative securities directly.
Quoin Pharmaceuticals reported that director Natalie Leong received a grant of share options for 12,211 American Depositary Shares (ADSs) on February 4, 2026. The options have an exercise price of $7.37 per ADS and expire on February 4, 2036. Each ADS represents 35 ordinary shares of the company.
The option vests over four years, with 20% vesting on each of February 4, 2027, 2028, and 2029, and the remaining 40% vesting on February 4, 2030. Following this grant, Leong holds 12,211 derivative securities directly.
Quoin Pharmaceuticals, Ltd. reported a new stock option grant to its Chief Financial Officer, Sally Bridget Lawlor, in a Form 4 filing. The grant covers an option to buy 10,330 American Depositary Shares (ADSs) at an exercise price of $19.36 per ADS, with each ADS representing thirty-five ordinary shares of Quoin. The option was approved by the company’s Compensation Committee on December 1, 2025 and expires on December 1, 2035.
The option vests over four years, with 20% of the ADSs vesting on each of December 1, 2026, 2027 and 2028, and the remaining 40% vesting on December 1, 2029. This filing reflects an equity-based component of the CFO’s compensation, designed to align her interests with long-term shareholder value.
Quoin Pharmaceuticals (QNRX) director Dennis Langer reported a purchase of 15,152 ADS on 10/14/2025 at a combined price of $8.49 per ADS in a private placement. Each ADS was purchased together with one Series H, Series I, Series J, and Series K warrant to buy one ADS.
The filing lists warrants for 15,152 ADS each with exercise prices of $9.075 (Series H), $10.3125 (Series I), and $12.375 (Series J and K). The warrants were exercisable immediately, subject to a beneficial ownership cap, and include milestone-based expirations tied to FDA-related events or a Priority Review Voucher sale, or five years from the closing date, whichever occurs earlier as specified for each series.
Following the reported transactions, Langer beneficially owned 15,153 ADS directly. Each ADS represents 35 ordinary shares of the company.